Mirum reports Phase 3 EXPAND topline for LIVMARLI in ultra-rare cholestatic liver diseases, biliary atresia included, on its Monday Oct 12 call. That readout is the whole label-expansion story for a r

What happened: Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will host an investor call on Monday, October 12, 2026 to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases, including biliary atresia. Key numbers: Call at 8:30 a.m. ET/5:30 a.m. PT on October 12, 2026. Access code 486697901. Why it matters: The call will disclose topline results from a Phase 3 study evaluating LIVMARLI for cholestatic pruritus in patients aged 6 months or older, an expansion beyond its approved uses in ALGS and PFIC.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will host an investor call on Monday, October 12, 2026 to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases, including biliary atresia.

The call will disclose topline results from a Phase 3 study evaluating LIVMARLI for cholestatic pruritus in patients aged 6 months or older, an expansion beyond its approved uses in ALGS and PFIC.